Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics symbols : SRNE save search
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Published: 2023-09-07 (Crawled : 13:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 0.52%
H: 42.58%
C: 36.03%
osteoarthritis positive treatment trial therapeutics results
Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus
Published: 2022-12-06 (Crawled : 18:00) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 1.68%
H: 0.0%
C: -7.02%
sti-1557 fda clearance trials vaccine mrna virus therapeutics sars-cov-2
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology Conference
Published: 2022-10-26 (Crawled : 12:00) - nutriband.com
NTRB | $4.18 -2.11% -3.39% 24K
|
Manufacturing
|
| O: 0.24%
H: 10.71%
C: -0.95%
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -3.14%
H: 10.39%
C: 3.25%
conference therapeutics study phase 2b
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. with Results To Be Presented at the 2022 American College of Rheumatology Conference
Published: 2022-10-26 (Crawled : 12:00) - biospace.com/
NTRB | $4.18 -2.11% -3.39% 24K
|
Manufacturing
|
| O: 0.24%
H: 10.71%
C: -0.95%
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -3.14%
H: 10.39%
C: 3.25%
conference therapeutics study phase 2b
Sorrento Therapeutics to Participate in Key Opinion Leader Panel Discussion on “New Horizons for the Treatment of Non-small Cell Lung Cancer”
Published: 2022-10-06 (Crawled : 13:20) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -1.24%
H: 3.46%
C: -1.89%
treatment lung therapeutics
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Published: 2022-09-26 (Crawled : 14:00) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -0.65%
H: 5.19%
C: -1.95%
treatment osteoarthritis trial therapeutics phase 2
Sorrento Therapeutics to Participate in Morgan Stanley 20th Annual Global Healthcare Conference September 12-14
Published: 2022-09-08 (Crawled : 14:00) - biospace.com/
MS | News 0 d | $90.26 0.2% 0.0% 6.7M
|
Finance
|
| O: -0.38%
H: 2.27%
C: 2.21%
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -1.88%
H: 14.35%
C: 13.4%
global conference therapeutics
Sorrento Therapeutics Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients
Published: 2022-08-19 (Crawled : 13:20) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -2.44%
H: 0.69%
C: -7.0%
sti-1558 covid-19 clearance trial therapeutics china
Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19
Published: 2022-07-19 (Crawled : 19:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -0.37%
H: 14.02%
C: 6.27%
sti-1558 covid-19 fda clearance therapeutics
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster
Published: 2022-06-03 (Crawled : 15:20) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 8.18%
H: 2.33%
C: -0.58%
sti-1558 covid-19 treatment therapeutics
Caris Life Sciences, Prostate Cancer Clinical Trial Consortium and Sorrento Therapeutics Announce Collaboration to Advance Precision Medicine Development Using Comprehensive Genomic Profiling
Published: 2022-06-02 (Crawled : 11:00) - prnewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -5.64%
H: 0.0%
C: 0.0%
collaboration genomic trial therapeutics cancer prostate cancer
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management
Published: 2022-03-18 (Crawled : 14:00) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 0.0%
H: 5.41%
C: 1.16%
sp-102 program trial therapeutics phase 3
Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Become Publicly Traded Through a Merger With Vickers Vantage Corp. I
Published: 2022-03-17 (Crawled : 20:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 0.0%
H: 5.41%
C: 1.16%
therapeutics merge
SORRENTO THERAPEUTICS ANNOUNCES COVISHIELD (STI-9167), A BROAD-SPECTRUM NEUTRALIZING ANTIBODY, POTENTLY NEUTRALIZES OMICRON AND OMICRON (+R346K) VARIANTS OF SARS-COV-2
Published: 2022-01-20 (Crawled : 19:00) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 0.47%
H: 5.59%
C: -2.8%
sti-9167 therapeutics sars-cov-2 antibody
Sorrento Therapeutics Mexico Wins Tender to Sell COVISTIX Tests to Mexico City Government
Published: 2022-01-13 (Crawled : 15:30) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
therapeutics test
Sorrento Therapeutics Mexico Executes Second Contract for Sale of 10 Million COVISTIX Tests for Mexico Market
Published: 2021-12-27 (Crawled : 20:00) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 2.78%
H: 0.52%
C: -5.42%
contract therapeutics test
Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors
Published: 2021-12-20 (Crawled : 15:30) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -1.46%
H: 1.49%
C: -2.34%
sti-1386 fda clearance solid tumors application therapeutics fda clearance
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial
Published: 2021-12-09 (Crawled : 22:00) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 1.03%
H: 2.75%
C: -2.6%
sp-102 trial therapeutics opioid positive results phase 3 topline
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy
Published: 2021-12-09 (Crawled : 17:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 1.03%
H: 2.75%
C: -2.6%
sp-102 trial therapeutics potential opioid positive therapy results phase 3 topline
Sorrento Therapeutics’ Clinical Laboratory Receives Accreditation From the College of American Pathologists
Published: 2021-12-07 (Crawled : 19:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 6.57%
H: 14.77%
C: 11.21%
therapeutics
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.